Imbruvica Capsules and Tablets - NPS MedicineWise
Imbruvica Capsules and Tablets - NPS MedicineWise
Progression-free survival and overall survival for ibrutinib and... | Download Scientific Diagram
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Full article: Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3
Frontiers | Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
The role of MRD in CLL
Full article: Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3
British Journal of Haematology | Wiley Online Library
Percentages of undetectable MRD (uMRD) in peripheral blood (PB) and... | Download Scientific Diagram
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
Prediction of outcomes in cll patients treated with ibrutinib: validation of current prognostic models and development of a simplified three‐factor model | Request PDF
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Cancers | Free Full-Text | The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
Imbruvica Capsules and Tablets - NPS MedicineWise
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
PDF) Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
British Journal of Haematology | Wiley Online Library
PDF) Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
